PharmX Technologies (ASX:PHX) Asset Turnover: 0.21 (As of Dec. 2025)


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.13
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Asset Turnover?

PharmX Technologies ASX:PHX 40 Asset Turnover is 0.21 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. PharmX Technologies's Revenue for the six months ended in Dec. 2025 was A$3.82 Mil. PharmX Technologies's Total Assets for the quarter that ended in Dec. 2025 was A$18.42 Mil. Therefore, PharmX Technologies's Asset Turnover for the quarter that ended in Dec. 2025 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. PharmX Technologies's annualized ROE % for the quarter that ended in Dec. 2025 was -6.49%. It is also linked to ROA % through Du Pont Formula. PharmX Technologies's annualized ROA % for the quarter that ended in Dec. 2025 was -5.56%.

PharmX Technologies  (ASX:PHX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

PharmX Technologies's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-1.024/15.766
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.024 / 7.644)*(7.644 / 18.4155)*(18.4155/ 15.766)
=Net Margin %*Asset Turnover*Equity Multiplier
=-13.4 %*0.4151*1.1681
=ROA %*Equity Multiplier
=-5.56 %*1.1681
=-6.49 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

PharmX Technologies's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-1.024/18.4155
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.024 / 7.644)*(7.644 / 18.4155)
=Net Margin %*Asset Turnover
=-13.4 %*0.4151
=-5.56 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

PharmX Technologies Asset Turnover Related Terms

PharmX Technologies Asset Turnover Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Asset Turnover Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.38 0.18 0.20 0.30

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.11 0.15 0.20 0.21

ASX:PHX vs VEEV, BTSG, TEM: Asset Turnover Comparison

For the Health Information Services subindustry, PharmX Technologies's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmX Technologies Asset Turnover vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Asset Turnover distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's Asset Turnover falls into.


ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmX Technologies Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

PharmX Technologies's Asset Turnover for the fiscal year that ended in Jun. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2025 )/( (Total Assets (A: Jun. 2024 )+Total Assets (A: Jun. 2025 ))/ count )
=7.32/( (29.857+18.825)/ 2 )
=7.32/24.341
=0.30

PharmX Technologies's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=3.822/( (18.825+18.006)/ 2 )
=3.822/18.4155
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.21 mean?
PharmX Technologies (ASX:PHX) has a Asset Turnover of 0.21 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Asset Turnover too high?
PharmX Technologies' current Asset Turnover is 0.21. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Asset Turnover compare to VEEV and BTSG?
PharmX Technologies' Asset Turnover of 0.21 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Healthcare Providers & Services company?
A good Asset Turnover depends on the Healthcare Providers & Services industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Asset Turnover is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current Asset Turnover is 0.21. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Asset Turnover is 0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Asset Turnover: 0.21
  • GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.07
GF Value